Metastasis‐free survival of uveal melanoma by tumour size category based on The Cancer Genome Atlas ( TCGA ) classification in 1001 cases
Clinical & Experimental Ophthalmology · 2025
DOI: 10.1111/ceo.14446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Ophthalmology, 2025. Verfasst von Rolika Bansal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Melanoma, Uveal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Jerry A Shields MD Eye Cancer Fund, Philadelphia, PA (CLS), Eye Tumor Research Foundation, Philadelphia, PA (CLS).
Abstract (Originalsprache)
Background
Uveal melanoma (UM) can be classified by tumour size category and by The Cancer Genome Atlas (TCGA) groups (cytogenetic‐based, 4‐category prognostic classification into Groups A‐D). This study was conducted to assess impact on metastasis‐free survival (MFS) in UM by tumour size category based on correlation with TCGA classification.
Methods
Retrospective analysis of 1001 cases categorised as small (0.0–3.0 mm), medium (3.1–8.0 mm) and large (≥8.1 mm), grouped by TCGA classification.
Results
Of 1001 cases, TCGA Groups (A/B/C/D) included small ( n = 270, 75%/11%/13%/1%), medium ( n = 503, 46%/14%/27%/13%) and large ( n = 228, 23%/19%/38%/20%) UM. The 5‐and 10‐year Kaplan–Meier MFS for small UM revealed Group A (98%, 98%), Group B (100%, 100%), Group C (86%, NA) and Group D (100%, NA). For medium UM, the values dropped with Group A (95%, 93%), Group B (90%, 90%), Group C (68%, 38%), and Group D (44%, NA). For large UM, the values dropped further with Group A (94%, 86%), Group B (85%, NA), Group C (40%, 28%), and Group D (23%, NA). Additionally, a comparison (small vs. medium vs. large tumour size category) revealed TCGA low‐risk grouping (Groups A or B) in 86% vs. 60% vs. 58% cases with UM.
Conclusion
By tumour size category, favourable cytogenetics (Groups A or B) is found in 86% of small tumours, 60% of medium tumours, and 58% of large tumours. The MFS at 10 years for favourable cytogenetics was 98% for small tumours, 92% for medium tumours, and 54% for large tumours. Tumour size category can serve as a surrogate for TCGA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Department of Genetics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Rolika Bansal, Hidayet Sener, Carol L Shields
Förderung
- Jerry A Shields MD Eye Cancer Fund, Philadelphia, PA (CLS)
- Eye Tumor Research Foundation, Philadelphia, PA (CLS)
Zitieren
APA
Bansal, R., Sener, H., Ganguly, A., Shields, J. A., & Shields, C. L. (2025). Metastasis‐free survival of uveal melanoma by tumour size category based on The Cancer Genome Atlas ( TCGA ) classification in 1001 cases. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.14446
Vancouver
Bansal R, Sener H, Ganguly A, Shields JA, Shields CL. Metastasis‐free survival of uveal melanoma by tumour size category based on The Cancer Genome Atlas ( TCGA ) classification in 1001 cases. Clinical & Experimental Ophthalmology. 2025. doi:10.1111/ceo.14446
BibTeX
@article{Bansal2025,
author = {Bansal, Rolika and Sener, Hidayet and Ganguly, Arupa and Shields, Jerry A and Shields, Carol L},
title = {Metastasis‐free survival of uveal melanoma by tumour size category based on The Cancer Genome Atlas ( TCGA ) classification in 1001 cases},
journal = {Clinical & Experimental Ophthalmology},
year = {2025},
doi = {10.1111/ceo.14446}
}
EUVIMED